Compare Amgen, Inc. (AMGN) vs Suncor Energy Inc. (SU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Suncor Energy Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Suncor Energy Inc. trades at $59.31 (market cap $69.71B). The key difference: Amgen, Inc. is far larger — about 2.8× Suncor Energy Inc.'s market cap, and Suncor Energy Inc. pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| AMGN | SU | |
|---|---|---|
Market Cap | $196.12B | $69.71B |
Sector | Health | Energy |
52-Week High | $388.16 | $69.73 |
52-Week Low | $271.18 | $38.17 |
Enterprise Value | $241.41B | $77.84B |
Dividend Yield | 2.77% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Suncor Energy (SU) trades at $59.25, up 1.3% today, with strong analyst support (74% buy ratings) and bullish technical signals. The stock shows solid fundamentals with a P/E of 15.99, net margin of 11.62%, and consistent dividend payments. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 results exceeded forecasts. Cash flow remains positive with $166M net inflow in 2025.
Outlook remains positive with expected revenue growth to $54.5B in 2026 and improving profit margins. Key risks include oil price volatility and operational challenges. The stock presents value opportunity with attractive valuation metrics and strong institutional support, though investors should monitor Q2 2026 earnings results against the $2.26 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
